Exosome-related technologies have been developing rapidly

over the past few years and substantial growth is expected for

the market as they get integrated into the fields of liquid biopsy,

precision medicine and regenerative medicine.

In particular, cancer derived exosomes influence the invasive

potential of cells by regulating angiogenesis, metastasis, and

immunity, making them an extremely useful source of

biomarkers for use in cancer detection, diagnosis, and

therapeutic selection.

In May 2017, ExCoBio Inc. raised US $11 million in a Series

A funding round. ExoCoBio is a venture-backed startup that

develops exosome- based cosmeceuticals and

biopharmaceuticals for skin and tissue regeneration that is

headquartered in South Korea Companies Mentioned Include:

· Anjarium Biosciences

· Avalon GloboCare Corp.

· Beckman Coulter

· Capricor Therapeutics

· Cavadis B.V.

· Cell Guidance Systems

· Codiak Biosciences

· CosmoBio USA

· Creative Medical Technologies Holdings

· Exiqon

· ExoCoBio Inc.

· Exerkine Corporation

· Exopharm

· Exosome Diagnostics

· Evox Therapeutics

· Exogenus Therapeutics

· Exosome Sciences

· Exosomics Siena SpA

· Exostemtech Co. Ltd.

· Exovita Biosciences

· Galen Lab Supplies

· Guangzhou Selaira Stem Cell Technology Co., Ltd

· HansaBioMed Life Sciences

· iZon Science

· Kimera Labs

· Lonza

· Miltenyi Biotec

· Norgen Biotek

· ReNeuron

· RoosterBio

· Unicyte AG

· VivaZome Therapeutics

· ZenBio

<BioInformant> 2018. 3.23